Start free

Bionano Genomics, Inc. (BNGO) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Sep 9, 2026.

Filings shown
15
Open-market buys
2
Open-market sells
0
Buys, 10b5-1 box not checked
2 of 2

Counts cover the 15 most recent Form 4 filings Tradune holds for BNGO (filed May 14 – Sep 9, 2026); the score below covers only the trailing 90 days (1 buy, 0 sells). SEC EDGAR Form 4 filings for BNGO last checked Nov 21, 2026, 09:00 UTC; the latest BNGO filing Tradune holds was filed Sep 9, 2026. This is not guaranteed to be the complete record — see BNGO's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 1 filing Tradune holds for BNGO filed Sep 9, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Albert LudererInterim Chief Executive 1 0 4,000 — +$4,845

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

56/ 100

Net insider purchases
1 distinct buyer1 buy · 0 sell txofficer buying

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at BNGO

Insiders reported 2 open-market purchases of BNGO between May 14, 2026 and Sep 9, 2026, across 1 distinct buyer. The most recent purchase was reported by Albert Luderer (Interim Chief Executive) on Sep 4, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Albert Luderer Interim Chief Executive · filed Sep 9, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 4,000 $1.21 8,000 (indirect) +100% Sep 4, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Albert Luderer Interim Chief Executive · filed Aug 21, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 4,000 $1.22 4,000 (indirect) — Aug 21, 2026
Alex Reid Hastie Chief Scientific Officer · filed Aug 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 54,000 — — — Aug 3, 2026
Mark Adamchak Principal Accounting Officer · filed Aug 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 5,000 — — — Aug 3, 2026
Jonathan V. Dixon General Counsel · filed Aug 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 15,000 — — — Aug 3, 2026
Mark Oldakowski Chief Operating Officer · filed Aug 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 15,000 — — — Aug 3, 2026
Mark Adamchak Principal Accounting Officer · filed Jun 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 7 $1.30 253 −2.7% Jun 3, 2026
Jonathan V. Dixon GENERAL COUNSEL · filed Jun 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 24 $1.30 239 −9.1% Jun 3, 2026
Alka Chaubey CHIEF MEDICAL OFFICER · filed Jun 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 24 $1.30 620 −3.7% Jun 3, 2026
Mark Oldakowski CHIEF OPERATING OFFICER · filed Jun 3, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Tax withholding 27 $1.30 868 −3.0% Jun 3, 2026
Aleksandar Rajkovic Director · filed May 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 9,149 — — — May 14, 2026
Yvonne Linney Director · filed May 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 9,149 — — — May 14, 2026
Kristiina Md Vuori Director · filed May 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 9,149 — — — May 14, 2026
Christopher J. Twomey Director · filed May 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 9,149 — — — May 14, 2026
David L. Barker Director · filed May 14, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Grant / award Stock Option (Right to Buy) 9,149 — — — May 14, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to BNGO's (Sep 9, 2026).

Frequently asked about BNGO insider activity

How many insiders bought BNGO stock in these Form 4 filings?

1 distinct insider at Bionano Genomics, Inc. reported 2 open-market purchases (Form 4 code P) of BNGO shares between May 14, 2026 and Sep 9, 2026, the most recent filed by Albert Luderer (Interim Chief Executive) on Sep 4, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for BNGO?

The most recent Form 4 on this page was filed by Albert Luderer (Interim Chief Executive) on Sep 9, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market BNGO insider purchase shown?

The largest open-market purchase among the filings shown was 4,000 BNGO shares at $1.22 (about $4,860) by Albert Luderer (Interim Chief Executive) on Aug 21, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent BNGO insider purchases have the Form 4 10b5-1 box checked?

No. All 2 BNGO open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Albert Luderer (Interim Chief Executive) on Sep 4, 2026, 4,000 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for BNGO — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.